BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Molecular Devices, Inc. (MDCC) Forms Scientific Advisory Board


7/25/2012 9:45:22 AM

Sunnyvale, CA, July 25, 2012: Molecular Devices, LLC, today announced the formation of its Scientific Advisory Board (SAB). Comprising experts from a range of fields including stem cell research, biotherapeutics and cell signalling, the SAB will advise on strategy, product applications and product innovation, with the aim of identifying evolving customer needs and ensuring that the Molecular Devices products continue to deliver maximum value.

The SAB has been formed to provide scientific input into new product development, and to keep Molecular Devices focused on customer needs for products that support leading edge research. These products include systems such as plate readers, imaging systems, or automated electrophysiology platforms, as well as emerging technologies.

Members of the Molecular Devices SAB are:

• Prof Sean J. Morrison, Director of the Children's Research Institute and Mary McDermott Cook Chair in Pediatric Genetics at University of Texas Southwestern, and Investigator of the Howard Hughes Medical Institute. Prof Morrison is an expert in stem cell biology and the mechanisms by which stem cells are hijacked by cancer cells to enable neoplastic proliferation and metastasis.

• Prof Tobias Meyer, Chair of the Department of Chemical & Systems Biology at Stanford University School of Medicine. Prof Meyer’s areas of expertise are the fields of pharmacology and signal transduction. His laboratory is developing microscopy and mathematical modeling approaches to understand how cells make decisions and regulate complex processes such as cell proliferation and cell migration.

• Prof Paul Johnston, Associate Professor of the Department of Pharmaceutical Sciences at University of Pittsburgh. Prof Johnston pioneered the use of high content imaging in drug discovery, and is an innovator of cell based approaches for lead generation and optimization. He developed numerous high throughput screening assays and hit assessment campaigns for kinases, transporters, GPCRs and ion channel targets.

• Prof Tobin J. Dickerson, Assistant Professor in the Department of Chemistry at Scripps Research Institute and founding member of the Worm Institute of Research and Medicine (WIRM). Prof Dickerson brings expertise in neural stem cell differentiation, protein-ligand interaction screening, HTS assay development and medicinal chemistry for diagnosis and treatment of chronic infections including the discovery of potent small molecule inhibitors of botulinum neurotoxin.

• Dr Pam Hawley-Nelson, Associate Director for Process Cell Culture at MedImmune. Dr Hawley-Nelson brings 18 years of experience in research and development of novel protein expression technologies, and in the development of cell lines for production of antibody pharmaceuticals.

"We are very pleased to bring together these key thought leaders to establish our Scientific Advisory Board," commented Kevin Chance, President of Molecular Devices. "Their deep insight into the emerging needs of researchers in the life sciences will be instrumental in directing innovation at Molecular Devices. Securing the interest of and direct interaction with these world class scientists through our SAB reflects the commitment the company has made to being a scientific leader in the market."

About Molecular Devices, LLC

Molecular Devices is one of the world’s leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics

Molecular Devices is committed to the continual development of innovative solutions for life science applications. The Company is headquartered in Silicon Valley with offices around the globe.

For more information about the complete product portfolio, visit www.moleculardevices.com

Contacts:

Molecular Devices:

Evan F Cromwell, PhD

Global Lead Scientist, BioResearch

Tel: 001 408 747 3523

Email: evan.cromwell@moldev.com

Media enquiries

Katie Odgaard

Zyme Communications

Tel: +44 (0) 7787 502 947

Email: Katie.odgaard@zymecommunications.com

Twitter: zymecomms



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES